Communication - IIS Aragón

6 March, 2024

The Miguel Servet Hospital performs the first kidney implant with a device that improves the conditions of the organ before the transplant

This intervention, in which researchers from IIS Aragón participated, is part of a national clinical trial and is the first kidney transplant with these conditions.
4 March, 2024

The IIS Aragón delivers the diplomas to the students of the IES Miguel Catalán who have participated in a scientific initiative

The project "Afternoons in the IIS Aragón laboratory: immersion in science for high school students" arises from IIS Aragón researchers Cecilia Pesini and Ariel Ramírez.
29 February, 2024

The IIS Aragón works on several lines of research in rare diseases with important international recognition

The Gaucher Disease and Hematological Neoplasms Study Group of the IIS Aragón is working on several lines of research on lysosomal storage diseases (LDS).
28 February, 2024

Researchers from the IIS Aragón have participated in a study on the effectiveness of dry needling for improving gait in patients with multiple sclerosis

The iHealthy research group participates in a study that seeks to evaluate the effectiveness of the “dry needling” technique in improving gait disorders in patients with multiple sclerosis.
27 February, 2024

The IIS Aragón and Ibercaja Foundation bring together the importance of taking care of cardiovascular health

Mental health, obesity, thyroid disease and the importance of health control are the topics that will be addressed at each of the meetings by doctors and researchers.
20 February, 2024

The Aragonese vaccine against tuberculosis could reach the market in 2027 or 2028

Designed by the University of Zaragoza, with the professor of Microbiology and researcher at the IIS Aragón Carlos Martín at the helm, and developed by the Galician biopharmaceutical company Biofabri.